Advanced NanoTherapies, Inc., a company focused on developing novel medical devices, has secured $31.0M in Series B funding. The round saw participation from S3 Ventures, a strategic investor, and T45 Fund, providing a significant capital injection for its work in cardiovascular health.
The company's technology is based on biodegradable nanoparticles designed for higher vascular uptake and cellular retention. This approach underpins its Sirolimus-based devices, which aim to treat atherosclerosis and blockages associated with Coronary Artery Disease (CAD) and Peripheral Artery Disease (PAD).















